Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by ImmunoBrain Checkpoint

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IBC-Ab002

            Therapeutic Area: Neurology Product Name: IBC-Ab002

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Alzheimer’s Association

            Deal Size: $1.0 million Upfront Cash: Undisclosed

            Deal Type: Funding September 01, 2020

            Details:

            The grant will phase 1 clinical trial to examine safety and activity of its proprietary antibody, IBC-Ab002, targeted to enhance the immune system and induce brain repair processes in individuals with Alzheimer’s disease.